Project R-12991

Development of a Treg-based cell therapy for multiple sclerosis (Research)

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). One of the first and most crucial events in MS pathogenesis is migration of immune cells into the CNS. Here, they induce neuronal damage, leading to a disturbed signal transduction to peripheral organs, resulting in the well-known disabling MS symptoms. Our previous findings show that regulatory T cells (Tregs) are negatively influenced by migrating into the CNS. In this study, results are translated into the development of a cell product containing adapted Tregs as an innovative treatment for MS patients

01 October 2022 - 30 September 2023